-
Success of GLP-1 receptor agonists in kidney disease halts FLOW trial early
Diabetes is the leading cause of chronic kidney disease. Glucagon-like peptide-1 (GLP-1) receptor agonists hold promise as an effective new therapy to combat this condition. Richard E. Pratley, MD, and other researchers will share new data on the renal and cardiovascular benefits of GLP-1 receptor agonists.
-
SELECT trial demonstrates semaglutide benefits beyond reduction of cardiovascular events
Although SELECT was not designed as a diabetes prevention study, investigators have found clinical benefits for these patients. Using a glucagon-like peptide-1 (GLP-1) receptor agonist can reduce risk of progressing to diabetes, for example, said Steven E. Kahn, MB, ChB, one of the panelists in a symposium that will examine SELECT trial results.
Looking Ahead to the 84th Scientific Sessions
-
Ask the Expert session to analyze evolutions in diabetes clinical care spurred by AI
Artificial intelligence (AI) is shaping the future of diabetes data science, the structure of multidisciplinary care teams, and the devices used to manage diabetes. Boris Kovatchev, PhD, and other experts will hold a multifaceted discussion analyzing several applications of AI in the clinical setting.
-
Access to new antiobesity drugs illustrates ongoing pharmacoequity challenges
Experts including Utibe Essien, MD, MPH, and Alison Sexton Ward, PhD, will address the goal of ensuring that all patients have equal and affordable access to the highest quality medication to manage their health needs.
-
Symposium to show how diabetes both causes and complicates organ transplantation
Archana R. Sadhu, MD, FACE, and other panelists will explain how diabetes and organ transplantation can increase risks for cardiovascular disease and other metabolic complications, whether the transplantation is a result of organ failure stemming from diabetes or diabetes is a new condition following transplantation.
-
Scientific Sessions showcases groundbreaking science advancing diabetes research, prevention, and care
More than 200 sessions and 1,400 posters will be presented from June 21-24 in Orlando. Scientific Sessions Meeting Planning Committee Chair Alice Y.Y. Cheng, MD, FRCPC, outlines the professional education and networking opportunities that await attendees, including new data from several clinical trials.
-
Program highlights to add to your Orlando itinerary
Scientific Sessions Meeting Planning Committee Chair Alice Y.Y. Cheng, MD, FRCPC, identifies high-interest sessions at the 84th Scientific Sessions attendees won’t want to miss. Full, in-person meeting registration includes access to on-demand recordings of sessions through Aug. 26.
-
Register now for the 84th Scientific Sessions
Take advantage of advance registration rates for the Scientific Sessions. More than 200 sessions will be presented onsite during the meeting, June 21-24 in Orlando, Florida. Marlon Pragnell, PhD, ADA Vice President of Research & Science, details the educational and networking opportunities that await.